A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia

Phase 2

Completed

• Conditions: Friedreich's Ataxia
• Interventions: Drug: Deferiprone oral solution 100mg/mL; Drug: Deferiprone oral solution 100 mg/mL

• Registration Number: NCT00897221
• Lead Sponsor: ApoPharma

Brief Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of deferiprone in subjects with Friedreich's ataxia (FRDA).

The secondary objective is to evaluate the long-term efficacy of deferiprone for the treatment of FRDA.

The tertiary objectives are to evaluate the effect of deferiprone on:

1. cardiac function,

2. quality of life, and

3. functional status.

Detailed Description

This is a multi-centre, open-label, non-randomized, single treatment, safety and efficacy study. All subjects who completed the LA29-0207 study are eligible for participation. Participants will receive deferiprone oral solution at the same dose (20 or 40 mg/kg/day) that they were assigned for LA29-0207. The duration of treatment will be 52 weeks.

Study Timeline

• Study First Submitted: 2009-05-08
• Study First Submitted QC: 2009-05-08
• Study First Posted: 2009-05-12
• Study Start: 2009-06
• Primary Completion: 2011-03
• Study Completion: 2011-03
• Status Verified: 2011-06
• Last Update Submitted: 2011-06-24
• Last Update Posted: 2011-06-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

1. Subjects who completed the ApoPharma study LA29-0207
2. Female subjects of childbearing potential must have a negative pregnancy test.
3. Male subjects must confirm that he and/or his female partner will use an effective method of contraception for the length of the trial and for 30 days following completion of the study or early termination.
4. Signed and witnessed written informed consent/assent, obtained prior to the first study intervention, as well as the ability to adhere to study restrictions, appointments and evaluation schedules.

Exclusion Criteria

1. Serum Ferritin and Hemoglobin (Hb) levels are below the reference range for age and sex-matched controls.
2. Unable to complete T25FW AND with a score > 5 minutes in the 9HPT. Subjects who can complete T25FW or with a score ≤ 5 minutes in the 9HPT will be allowed to enrol).
3. Doubling of score on 9HPT or T25FW compared to their study baseline results in LA29-0207.
4. History or evidence of neutropenia/agranulocytosis defined by a confirmed absolute neutrophil count (ANC) < 1.5 x 109/L or thrombocytopenia defined by a platelet count <150 x 109/L.
5. Occurrence of SAEs or any other AEs during the LA29-0207 study, which in the opinion of the investigator cause the patient's participation in the extension study to be inappropriate.
6. Unable to comply with requirements of the protocol.
7. Pregnant, breastfeeding or planning to become pregnant during the study period.
8. QTc interval >450ms.
9. Have been on antioxidants prior to start of study treatment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dose 1	Deferiprone oral solution 100mg/mL	Deferiprone oral solution 20 mg/kg/day
Dose 2	Deferiprone oral solution 100 mg/mL	Deferiprone oral solution 40 mg/kg/day

Primary Outcome Measures

Name	Time	Method
The patient's long-term tolerance of treatment will be assessed by the occurence of adverse events.	52 weeks

Secondary Outcome Measures

Name	Time	Method
The long-term efficacy of deferiprone will be assessed. Efficacy measures include the 9HPT, T25FW, LCLA, ICARS and FARS.	52 weeks

Trial Locations

Locations (4)

Hospital Erasme; 🇧🇪 Brussels, Belgium

Hospital Necker-Enfants Malades; 🇫🇷 Paris, France

Fondazione IRCCS Istituto Neurologico "C. Besta"; 🇮🇹 Milan, Italy

La Fundacion Para la Investigacion Biomedica; 🇪🇸 Madrid, Spain